PTSD, depression and the Spravato question on MO HealthNet

If you live with PTSD, you have probably noticed that it rarely travels alone. Sleep goes. Mood sinks. The medicines you were given took the edge off some things and not others. At some point you may hear about a nasal spray called Spravato and wonder whether it is meant for you.

This FAQ is for Missourians covered by MO HealthNet who are sorting through that question. It draws on our publisher's paid survey of 443 Midwest adults, and it tries to be careful about what that survey can and cannot tell you.

Is Spravato approved for PTSD?

No. This is the most important answer on this page. Spravato, an esketamine nasal spray, holds FDA approval in adults for two things: treatment-resistant depression, and major depression in the presence of acute suicidal thoughts or behavior. PTSD itself is not an approved use.

Researchers have studied ketamine-related drugs in PTSD, but a study is not an approval. Anyone who tells you esketamine is a PTSD treatment is overstating the evidence. A plain summary of what Spravato is approved for spells this out.

Then why does it come up for people with PTSD?

Because depression and PTSD so often occur together. If you have PTSD alongside major depression that stayed after two or more antidepressants, the depression part of your picture might be something a clinician would evaluate for esketamine. That decision belongs to a clinician who knows your full history.

The overlap is common. In our survey, 72 percent of respondents described depression, anxiety, or PTSD that standard medicine could not settle, in themselves, a loved one, or both; 37 percent meant themselves. That is a general-population sample, not a PTSD clinic, and it still found this struggle nearly everywhere.

What does treat PTSD?

Trauma-focused talk therapies carry the strongest evidence, including prolonged exposure therapy, cognitive processing therapy, or EMDR. Sertraline and paroxetine are the two antidepressants with FDA approval for PTSD. Other medications are sometimes used to target specific symptoms like nightmares. If you have not had a real course of trauma-focused therapy, that is worth raising with a provider.

Is mental health care part of MO HealthNet?

It is. Missouri Medicaid covers behavioral health services, including visits with mental health providers and prescription medications. Exactly which therapists, programs, and drugs are available depends on your health plan. Calling the member line on your plan card is the fastest way to find in-network providers who treat trauma.

Community mental health centers across Missouri also serve Medicaid members and can be a practical starting point if you do not already have a therapist.

Would MO HealthNet cover esketamine if a doctor thought I needed it for depression?

We cannot promise what any plan will do. What is common across insurers, including Medicaid plans, is prior authorization for newer medicines. Your prescriber would usually need to document your diagnosis and the antidepressants you have tried. Call your plan and ask whether esketamine is covered and what the requirements are.

If coverage is your first question, you are like most people we surveyed. Insurance coverage was one of the two things 85 percent of respondents said matter most in picking a provider; for the 163 respondents on Medicaid, it was 90 percent. Being close to home, the next most chosen, was picked by 43 percent.

Spravato was news to me. Is that unusual?

No. It would be more unusual if you knew it. In our survey, the name was unfamiliar to 73 percent, and another 21 percent had seen it without learning what it was. The people who could accurately describe it made up 6 percent. Those figures are final.

What did people with struggles like mine actually search for?

Respondents wrote down their likely search phrases, and the answers were blunt: "ptsd help," one wrote; another, "someone please help me." Not one of them was a drug name.

Those searches tend to surface directories and ads. A conversation with a provider will get you further than any results page.

Who should I talk to first?

Most respondents would start with their primary care doctor, 56 percent, and another 23 percent would head to a psychiatrist or other mental health provider. Either door works. A primary care provider can screen for depression and PTSD, check for medical causes, and refer you. A psychiatrist can go deeper on medication options.

If you are a veteran or part of a military family, you may have TRICARE alongside Medicaid. Ask your doctor how the two fit together before you book anything.

What should I say?

Try something like this:

"I have PTSD, and I also feel depressed most days. I've tried these medications and they haven't helped enough. What are my options for the trauma, and what are my options for the depression?"

Separating the two questions helps the clinician think about each. If you want to ask about esketamine specifically, you can add: "Is my depression the kind that esketamine is approved for?"

What if a session would be hard for me?

Esketamine can cause a temporary feeling of detachment or dissociation, and some people with trauma histories may find that unsettling. Sessions happen in a monitored clinical setting, and staff observe you for at least two hours. If you are worried about how you would handle it, tell the clinician before any decision is made. That concern is legitimate and should be part of the conversation.

How would I get there and back?

You cannot drive after a session until the next day after a night's sleep. Ask your plan whether non-emergency medical transportation covers trips to a certified center, or plan on a friend or relative for the first several weeks, when visits usually happen twice a week.

If I am in crisis right now?

Skip the wait for an appointment. The Suicide and Crisis Lifeline is reachable around the clock at 988, by phone or by text; veterans can press 1. Talking to someone tonight is the right move.

Methodology

This FAQ rests on a Pollfish consumer panel survey that 443 people, ages 18 to 64, completed by June 23, 2026, in Nebraska, Kansas, Missouri, Iowa, Oklahoma, Illinois, Wisconsin, Indiana, Minnesota, and Ohio. Apart from one Medicaid figure, the results cited are whole-sample; we did not break out people with PTSD. Each figure traces to the validated final export. Our publisher commissioned the study and paid its cost.